BioCentury | May 22, 2020
Product Development

May 21 Quick Takes: EC approves Zolgensma for SMA; plus Sunovion, Kadmon, Sorrento, tafasitamab, Zentalis’ new JV

Immediate access to Zolgensma in France  The European Commission conditionally approved Zolgensma onasemnogene abeparvovec from Novartis AG (NYSE:NVS; SIX:NOVN) to treat spinal muscular atrophy in babies and young children who have SMA Type 1 or...
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

Robert Hershberg has joined Frazier Healthcare Partners as venture partner. The former EVP, CSO and head of BD and global alliances of Celgene Corp. helped coordinate the company’s $74 billion takeout by Bristol Myers Squibb...
BioCentury | Apr 3, 2020
Deals

Servier adds mAb platform via takeout of former European biotech darling Symphogen

What was once a high-profile European biotech is now going out quietly as Servier is acquiring Danish mAb company Symphogen A/S for an undisclosed sum. The two companies are partnered across three clinical stage immuno-oncology...
BioCentury | Mar 3, 2020
Product Development

March 2 Quick Takes: FDA Priority Review for MorphoSys-Incyte lymphoma therapy; plus Pfizer-Lilly, Merck, AbbVie, Novartis, Cerovene

Priority Review for MorphoSys follows Incyte deal  FDA accepted and granted Priority Review to a BLA for tafasitamab from MorphoSys AG (NASDAQ:MOR; Xetra:MOR) to treat relapsed or refractory diffuse large B cell lymphoma in combination...
BC Extra | Jan 18, 2020
Financial News

I-Mab dips in NASDAQ debut, first in years for an innovative Chinese biopharma

Shares of I-Mab slipped 11% in their first day of trading Friday after the Shanghai-based company priced its IPO on NASDAQ within its proposed range, raising $104 million to fund its cross-border development strategy. The...
BC Extra | Jan 13, 2020
Company News

MorphoSys nets $900M up front in global deal with Incyte for anti-CD19 mAb

The first major deal under the watch of MorphoSys’ new CEO Jean-Paul Kress triples the German biotech’s cash position through a global partnership with Incyte to develop and commercialize blood cancer therapy tafasitamab. While the...
BC Extra | Jan 9, 2020
Clinical News

ADC’s loncastuximab data could clear path for BLA, IPO filing

Months after scuttling a planned listing, ADC Therapeutics intends to refile for an IPO as it prepares to submit a BLA in 3Q19 seeking accelerated approval for its antibody-drug conjugate to treat DLBCL in a...
BC Extra | Jan 4, 2020
Company News

Next act for BeiGene’s tislelizumab: a Leap deal for gastric cancer

Fresh off the approval of tislelizumab in China, BeiGene has partnered with Leap to pair the PD-1 inhibitor with the latter’s DKK1 inhibitor to create a combination therapy that could help treat cancers that don’t...
BC Extra | Dec 31, 2019
Company News

Dec. 31 Company Quick Takes: A first for BeiGene; plus MorphoSys, Junshi-CSPC, Acceleron-Fulcrum and Solasia-EditForce

First-ever China approval for homegrown BeiGene drug  China’s National Medical Products Administration approved anti-PD-1 mAb tislelizumab from BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) to treat classical Hodgkin lymphoma in a third-line setting. The approval is the first...
BC Extra | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

Sanofi (Euronext:SAN; NASDAQ:SNY) said Muzammil Mansuri, EVP, head of strategy and business development, will retire at the end of the month. His responsibilities will be divided between Alban de La Sablière, head of business development,...
Items per page:
1 - 10 of 845
BioCentury | May 22, 2020
Product Development

May 21 Quick Takes: EC approves Zolgensma for SMA; plus Sunovion, Kadmon, Sorrento, tafasitamab, Zentalis’ new JV

Immediate access to Zolgensma in France  The European Commission conditionally approved Zolgensma onasemnogene abeparvovec from Novartis AG (NYSE:NVS; SIX:NOVN) to treat spinal muscular atrophy in babies and young children who have SMA Type 1 or...
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

Robert Hershberg has joined Frazier Healthcare Partners as venture partner. The former EVP, CSO and head of BD and global alliances of Celgene Corp. helped coordinate the company’s $74 billion takeout by Bristol Myers Squibb...
BioCentury | Apr 3, 2020
Deals

Servier adds mAb platform via takeout of former European biotech darling Symphogen

What was once a high-profile European biotech is now going out quietly as Servier is acquiring Danish mAb company Symphogen A/S for an undisclosed sum. The two companies are partnered across three clinical stage immuno-oncology...
BioCentury | Mar 3, 2020
Product Development

March 2 Quick Takes: FDA Priority Review for MorphoSys-Incyte lymphoma therapy; plus Pfizer-Lilly, Merck, AbbVie, Novartis, Cerovene

Priority Review for MorphoSys follows Incyte deal  FDA accepted and granted Priority Review to a BLA for tafasitamab from MorphoSys AG (NASDAQ:MOR; Xetra:MOR) to treat relapsed or refractory diffuse large B cell lymphoma in combination...
BC Extra | Jan 18, 2020
Financial News

I-Mab dips in NASDAQ debut, first in years for an innovative Chinese biopharma

Shares of I-Mab slipped 11% in their first day of trading Friday after the Shanghai-based company priced its IPO on NASDAQ within its proposed range, raising $104 million to fund its cross-border development strategy. The...
BC Extra | Jan 13, 2020
Company News

MorphoSys nets $900M up front in global deal with Incyte for anti-CD19 mAb

The first major deal under the watch of MorphoSys’ new CEO Jean-Paul Kress triples the German biotech’s cash position through a global partnership with Incyte to develop and commercialize blood cancer therapy tafasitamab. While the...
BC Extra | Jan 9, 2020
Clinical News

ADC’s loncastuximab data could clear path for BLA, IPO filing

Months after scuttling a planned listing, ADC Therapeutics intends to refile for an IPO as it prepares to submit a BLA in 3Q19 seeking accelerated approval for its antibody-drug conjugate to treat DLBCL in a...
BC Extra | Jan 4, 2020
Company News

Next act for BeiGene’s tislelizumab: a Leap deal for gastric cancer

Fresh off the approval of tislelizumab in China, BeiGene has partnered with Leap to pair the PD-1 inhibitor with the latter’s DKK1 inhibitor to create a combination therapy that could help treat cancers that don’t...
BC Extra | Dec 31, 2019
Company News

Dec. 31 Company Quick Takes: A first for BeiGene; plus MorphoSys, Junshi-CSPC, Acceleron-Fulcrum and Solasia-EditForce

First-ever China approval for homegrown BeiGene drug  China’s National Medical Products Administration approved anti-PD-1 mAb tislelizumab from BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) to treat classical Hodgkin lymphoma in a third-line setting. The approval is the first...
BC Extra | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

Sanofi (Euronext:SAN; NASDAQ:SNY) said Muzammil Mansuri, EVP, head of strategy and business development, will retire at the end of the month. His responsibilities will be divided between Alban de La Sablière, head of business development,...
Items per page:
1 - 10 of 845